Abstract:Simple Summary The formats of bispecific antibody have been investigated for many years to enhance the stability of the structure and anti-tumor efficacy. One of the formats combining two Fabs at their C termini provides unmodified variable region and comparable activity to other fragment-based bispecific antibodies that are usually combined in a head-to-tail manner. However, the current strategy to produce the BiFab molecule is limited to a semisynthetic method that introduces unnatural amino acid to antibodies' sequences during production. To improve the application of BiFab format in investigational biodrugs, we have applied sortase A-mediated "bio-click" chemistry to generate BiFab, for facile assembly of Fab molecules that have been expressed and stored as BiFab module candidates. The BiFabs made by our method stimulate T cell proliferation and activation with favorable in vitro and in vivo anti-tumor activit. Our results indicate that BiFab made by sortase A-mediated click chemistry could be used to efficiently generate various BiFabs with high potency, which further supports personalized tumor immunotherapy in the future. Bispecific antibodies (BsAbs) for T cell engagement have shown great promise in cancer immunotherapy, and their clinical applications have been proven in treating hematological malignance. Bispecific antibody binding fragment (BiFab) represents a promising platform for generating non-Fc bispecific antibodies. However, the generation of BiFab is still challenging, especially by means of chemical conjugation. More conjugation strategies, e.g., enzymatic conjugation and modular BiFab preparation, are needed to improve the robustness and flexibility of BiFab preparation. We successfully used chemo-enzymatic conjugation approach to generate bispecific antibody (i.e., BiFab) with Fabs from full-length antibodies. Paired click handles (e.g., N-3 and DBCO) was introduced to the C-terminal LPETG tag of Fabs via sortase A mediated transpeptidation, followed by site-specific conjugation between two click handle-modified Fabs for BiFab generation. Both BiFab(CD20/CD3) (EC50 = 0.26 ng/mL) and BiFab(Her2/CD3) exhibited superior efficacy in mediating T cells, from either PBMC or ATC, to kill target tumor cell lines while spared antigen-negative tumor cells in vitro. The BiFab(CD20/CD3) also efficiently inhibited CD20-positive tumor growth in mouse xenograft model. We have established a facile sortase A-mediated click handle installation to generate homogeneous and functional BiFabs. The exemplary BiFabs against different targets showed superior efficacy in redirecting and activating T cells to specifically kill target tumor cells, demonstrating the robustness of sortase A-mediated "bio-click" chemistry in generating various potent BiFabs. This approach also holds promise for further efficient construction of a Fab derivative library for personalized tumor immunotherapy in the future.

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

Structural basis of a novel heterodimeric Fc for bispecific antibody production

Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life

Engineered Fc Based Antibody Domains and Fragments As Novel Scaffolds.

New protein engineering approaches to multivalent and bispecific antibody fragments

Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding

Structure-guided Design Fine-Tunes Pharmacokinetics, Tolerability, and Antitumor Profile of Multispecific Frizzled Antibodies

Engineering Bifunctional Antibodies With Constant Region Fusion Architectures

Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use

Soluble Monomeric IgG1 Fc

Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs

Facile Generation of Potent Bispecific Fab via Sortase A and Click Chemistry for Cancer Immunotherapy

Structural landscape of engineered multivalent antibody fragments and their application as crystallization scaffolds

Trimming Crystallizable Fragment (fc) Glycans Enables the Direct Enzymatic Transfer of Biomacromolecules to Antibodies As Therapeutics.

New Strategies for Cysteine Bioconjugation and Protein Cross-Linking

An Unexpected Single-step Glycosylation Enables the Construction of Antibody-Biomacromolecule Conjugates As Therapeutics

A general Fc engineering platform for the next generation of antibody therapeutics

Structure and Sequence Engineering Approaches to Improve In Vivo Expression of Nucleic Acid-Delivered Antibodies

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria

Modulating antibody effector functions by Fc glycoengineering